Alpine Associates Management Inc. lifted its holdings in shares of NxStage Medical, Inc. (NASDAQ:NXTM) by 1.1% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 4,035,237 shares of the medical device company’s stock after buying an additional 43,779 shares during the period. NxStage Medical accounts for approximately 3.5% of Alpine Associates Management Inc.’s holdings, making the stock its 8th biggest position. Alpine Associates Management Inc. owned 6.09% of NxStage Medical worth $97,774,000 as of its most recent SEC filing.
Several other large investors have also made changes to their positions in the stock. Public Employees Retirement Association of Colorado acquired a new stake in shares of NxStage Medical during the fourth quarter valued at approximately $128,000. Prudential Financial Inc. acquired a new stake in shares of NxStage Medical during the third quarter valued at approximately $202,000. Amalgamated Bank raised its holdings in shares of NxStage Medical by 7.1% during the second quarter. Amalgamated Bank now owns 8,357 shares of the medical device company’s stock valued at $210,000 after acquiring an additional 553 shares during the period. Athos Capital Ltd acquired a new stake in shares of NxStage Medical during the third quarter valued at approximately $557,000. Finally, Suntrust Banks Inc. raised its holdings in shares of NxStage Medical by 2.3% during the second quarter. Suntrust Banks Inc. now owns 9,480 shares of the medical device company’s stock valued at $237,000 after acquiring an additional 209 shares during the period. 83.23% of the stock is owned by institutional investors and hedge funds.
NxStage Medical, Inc. (NASDAQ NXTM) opened at $24.52 on Wednesday. NxStage Medical, Inc. has a one year low of $20.45 and a one year high of $30.80.
NXTM has been the topic of several research reports. ValuEngine lowered shares of NxStage Medical from a “hold” rating to a “sell” rating in a research note on Friday, February 2nd. Zacks Investment Research downgraded shares of NxStage Medical from a “hold” rating to a “sell” rating in a research report on Tuesday, November 14th. Northland Securities reissued a “hold” rating and issued a $30.00 target price on shares of NxStage Medical in a research report on Wednesday, November 8th. Finally, BidaskClub raised shares of NxStage Medical from a “strong sell” rating to a “sell” rating in a research report on Monday, February 5th. Three investment analysts have rated the stock with a sell rating and eight have assigned a hold rating to the stock. The stock presently has an average rating of “Hold” and an average price target of $30.25.
In related news, SVP Winifred L. Swan sold 3,500 shares of the stock in a transaction dated Wednesday, December 20th. The shares were sold at an average price of $25.35, for a total transaction of $88,725.00. Following the completion of the sale, the senior vice president now owns 14,270 shares in the company, valued at approximately $361,744.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 4.70% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This report was published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this report on another domain, it was stolen and republished in violation of U.S. & international trademark and copyright laws. The original version of this report can be read at https://www.dispatchtribunal.com/2018/02/21/nxstage-medical-inc-nxtm-is-alpine-associates-management-inc-s-8th-largest-position.html.
NxStage Medical Profile
NxStage Medical, Inc is a medical technology company. The Company develops, manufactures and markets products and services for patients suffering from chronic or acute kidney failure. It operates through three segments. The System One segment includes revenues from the sale and rental of the System One and PureFlow SL dialysate preparation equipment and the sale of disposable products in the home and critical care markets.
Receive News & Ratings for NxStage Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NxStage Medical and related companies with MarketBeat.com's FREE daily email newsletter.